Trends in incidence of youth-onset type 1 and type 2 diabetes in the USA, 2002-18: results from the population-based SEARCH for Diabetes in Youth study.


Journal

The lancet. Diabetes & endocrinology
ISSN: 2213-8595
Titre abrégé: Lancet Diabetes Endocrinol
Pays: England
ID NLM: 101618821

Informations de publication

Date de publication:
04 2023
Historique:
received: 25 08 2022
revised: 10 01 2023
accepted: 12 01 2023
pmc-release: 01 04 2024
pubmed: 4 3 2023
medline: 28 3 2023
entrez: 3 3 2023
Statut: ppublish

Résumé

The incidence of diabetes is increasing in children and young people. We aimed to describe the incidence of type 1 and type 2 diabetes in children and young people aged younger than 20 years over a 17-year period. The SEARCH for Diabetes in Youth study identified children and young people aged 0-19 years with a physician diagnosis of type 1 or type 2 diabetes at five centres in the USA between 2002 and 2018. Eligible participants included non-military and non-institutionalised individuals who resided in one of the study areas at the time of diagnosis. The number of children and young people at risk of diabetes was obtained from the census or health plan member counts. Generalised autoregressive moving average models were used to examine trends, and data are presented as incidence of type 1 diabetes per 100 000 children and young people younger than 20 years and incidence of type 2 diabetes per 100 000 children and young people aged between 10 years and younger than 20 years across categories of age, sex, race or ethnicity, geographical region, and month or season of diagnosis. We identified 18 169 children and young people aged 0-19 years with type 1 diabetes in 85 million person-years and 5293 children and young people aged 10-19 years with type 2 diabetes in 44 million person-years. In 2017-18, the annual incidence of type 1 diabetes was 22·2 per 100 000 and that of type 2 diabetes was 17·9 per 100 000. The model for trend captured both a linear effect and a moving-average effect, with a significant increasing (annual) linear effect for both type 1 diabetes (2·02% [95% CI 1·54-2·49]) and type 2 diabetes (5·31% [4·46-6·17]). Children and young people from racial and ethnic minority groups such as non-Hispanic Black and Hispanic children and young people had greater increases in incidence for both types of diabetes. Peak age at diagnosis was 10 years (95% CI 8-11) for type 1 diabetes and 16 years (16-17) for type 2 diabetes. Season was significant for type 1 diabetes (p=0·0062) and type 2 diabetes (p=0·0006), with a January peak in diagnoses of type 1 diabetes and an August peak in diagnoses of type 2 diabetes. The increasing incidence of type 1 and type 2 diabetes in children and young people in the USA will result in an expanding population of young adults at risk of developing early complications of diabetes whose health-care needs will exceed those of their peers. Findings regarding age and season of diagnosis will inform focused prevention efforts. US Centers for Disease Control and Prevention and US National Institutes of Health.

Sections du résumé

BACKGROUND
The incidence of diabetes is increasing in children and young people. We aimed to describe the incidence of type 1 and type 2 diabetes in children and young people aged younger than 20 years over a 17-year period.
METHODS
The SEARCH for Diabetes in Youth study identified children and young people aged 0-19 years with a physician diagnosis of type 1 or type 2 diabetes at five centres in the USA between 2002 and 2018. Eligible participants included non-military and non-institutionalised individuals who resided in one of the study areas at the time of diagnosis. The number of children and young people at risk of diabetes was obtained from the census or health plan member counts. Generalised autoregressive moving average models were used to examine trends, and data are presented as incidence of type 1 diabetes per 100 000 children and young people younger than 20 years and incidence of type 2 diabetes per 100 000 children and young people aged between 10 years and younger than 20 years across categories of age, sex, race or ethnicity, geographical region, and month or season of diagnosis.
FINDINGS
We identified 18 169 children and young people aged 0-19 years with type 1 diabetes in 85 million person-years and 5293 children and young people aged 10-19 years with type 2 diabetes in 44 million person-years. In 2017-18, the annual incidence of type 1 diabetes was 22·2 per 100 000 and that of type 2 diabetes was 17·9 per 100 000. The model for trend captured both a linear effect and a moving-average effect, with a significant increasing (annual) linear effect for both type 1 diabetes (2·02% [95% CI 1·54-2·49]) and type 2 diabetes (5·31% [4·46-6·17]). Children and young people from racial and ethnic minority groups such as non-Hispanic Black and Hispanic children and young people had greater increases in incidence for both types of diabetes. Peak age at diagnosis was 10 years (95% CI 8-11) for type 1 diabetes and 16 years (16-17) for type 2 diabetes. Season was significant for type 1 diabetes (p=0·0062) and type 2 diabetes (p=0·0006), with a January peak in diagnoses of type 1 diabetes and an August peak in diagnoses of type 2 diabetes.
INTERPRETATION
The increasing incidence of type 1 and type 2 diabetes in children and young people in the USA will result in an expanding population of young adults at risk of developing early complications of diabetes whose health-care needs will exceed those of their peers. Findings regarding age and season of diagnosis will inform focused prevention efforts.
FUNDING
US Centers for Disease Control and Prevention and US National Institutes of Health.

Identifiants

pubmed: 36868256
pii: S2213-8587(23)00025-6
doi: 10.1016/S2213-8587(23)00025-6
pmc: PMC10091237
mid: NIHMS1881252
pii:
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, U.S. Gov't, P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

242-250

Subventions

Organisme : NCCDPHP CDC HHS
ID : U18 DP006131
Pays : United States
Organisme : NCCDPHP CDC HHS
ID : U18 DP006133
Pays : United States
Organisme : NCCDPHP CDC HHS
ID : U18 DP006134
Pays : United States
Organisme : NCCDPHP CDC HHS
ID : U18 DP006136
Pays : United States
Organisme : NCCDPHP CDC HHS
ID : U18 DP006138
Pays : United States
Organisme : NCCDPHP CDC HHS
ID : U18 DP006139
Pays : United States

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2023 Elsevier Ltd. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of interests We declare no competing interests.

Références

Ann N Y Acad Sci. 2003 Nov;1005:13-22
pubmed: 14679036
Ann Epidemiol. 2014 Oct;24(10):727-33
pubmed: 25108688
Am J Epidemiol. 2015 Jan 1;181(1):32-9
pubmed: 25515167
JAMA. 2021 Aug 24;326(8):717-727
pubmed: 34427600
Diabetes Care. 2014 Dec;37(12):3336-44
pubmed: 25414389
MMWR Morb Mortal Wkly Rep. 2020 Feb 14;69(6):161-165
pubmed: 32053581
N Engl J Med. 2017 Apr 13;376(15):1419-1429
pubmed: 28402773
Diabetes Care. 2007 Jul;30(7):1758-63
pubmed: 17468358
Diabetologia. 2019 Mar;62(3):408-417
pubmed: 30483858
Diabetes Care. 2000 Jun;23(6):759-64
pubmed: 10840992
Lancet Diabetes Endocrinol. 2021 Apr;9(4):203-211
pubmed: 33636102
BMJ Open Diabetes Res Care. 2019 May 28;7(1):e000657
pubmed: 31245008
Pediatr Diabetes. 2015 Dec;16(8):573-80
pubmed: 25316271
Med J Aust. 2016 May 2;204(8):303
pubmed: 27125801
JAMA. 2014 May 7;311(17):1778-86
pubmed: 24794371
Diabetes Care. 2015 Jun;38(6):e84-5
pubmed: 25998301
Diabetes Care. 2021 Dec;44(12):2691-2698
pubmed: 34607833
JAMA. 2007 Jun 27;297(24):2765-6
pubmed: 17595280
Diabetes Care. 2016 May;39(5):823-9
pubmed: 27006511
Diabetes Res Clin Pract. 2021 May;175:108739
pubmed: 33711398
JAMA. 2017 Feb 28;317(8):825-835
pubmed: 28245334
Pediatr Endocrinol Rev. 2020 Mar;17(Suppl 1):198-209
pubmed: 32208564
Diabetes Res Clin Pract. 2022 Mar;185:109785
pubmed: 35189261
Diabet Med. 2018 Jun;35(6):737-744
pubmed: 29460341
NCHS Data Brief. 2017 Oct;(288):1-8
pubmed: 29155689

Auteurs

Lynne E Wagenknecht (LE)

Division of Public Health Sciences, Wake Forest University School of Medicine, Winston-Salem, NC, USA. Electronic address: lynne.wagenknecht@wakehealth.edu.

Jean M Lawrence (JM)

Division of Diabetes, Endocrinology, and Metabolic Diseases, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, USA.

Scott Isom (S)

Division of Public Health Sciences, Wake Forest University School of Medicine, Winston-Salem, NC, USA.

Elizabeth T Jensen (ET)

Division of Public Health Sciences, Wake Forest University School of Medicine, Winston-Salem, NC, USA.

Dana Dabelea (D)

Lifecourse Epidemiology of Adiposity and Diabetes Center, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.

Angela D Liese (AD)

Department of Epidemiology and Biostatistics, Arnold School of Public Health, University of South Carolina, Columbia, SC, USA.

Lawrence M Dolan (LM)

Department of Pediatrics, Cincinnati Children's Hospital, University of Cincinnati College of Medicine, Cincinnati, OH, USA.

Amy S Shah (AS)

Department of Pediatrics, Cincinnati Children's Hospital, University of Cincinnati College of Medicine, Cincinnati, OH, USA.

Anna Bellatorre (A)

Lifecourse Epidemiology of Adiposity and Diabetes Center, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.

Katherine Sauder (K)

Lifecourse Epidemiology of Adiposity and Diabetes Center, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.

Santica Marcovina (S)

Medpace Reference Laboratories, Cincinnati, OH, USA.

Kristi Reynolds (K)

Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USA.

Catherine Pihoker (C)

Department of Pediatrics, University of Washington, Seattle, WA, USA.

Giuseppina Imperatore (G)

Division of Diabetes Translation, Centers for Disease Control and Prevention, Atlanta, GA, USA.

Jasmin Divers (J)

Division of Health Services Research, Department of Foundations of Medicine, New York University Long Island School of Medicine, Mineola, NY, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH